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introduction
Lung cancer represents the leading cause of cancer mortality
worldwide, accounting for 1.2 million deaths each year.
Improving survival in lung cancer is a major challenge for
modern oncology considering that 5-year survival remains
<15%, across all stages of disease and with <7% of patients alive
10 years after diagnosis.
Because of the difficulties in significantly improving survival in
locally advanced and metastatic non-small-cell lung cancer
(NSCLC), diagnosis and treatment of early stages theoretically
represent the most consistent possibility of modifying the
outcome of NSCLC in terms of disease-free and overall survival.
lung cancer screening and staging
The large majority of NSCLC patients present with symptoms
in a late advanced stage and diagnosis occurs mostly in locally
advanced or metastatic disease with a very poor rate of cure.
The issue of lung cancer screening has consequently a strong
rationale, to increase the detection of early NSCLC potentially
cured by surgery. Earlier controlled trials, using standard
radiography and sputum cytology failed to demonstrate any
survival benefit for early detection in the interventional arm
versus controls. Subsequently using more sensitive screening
modalities such as low-dose CT scanning (LDCT) several
authors have demonstrated the possibility of detecting
approximately three times as many small lung nodules in
comparison with chest X-ray and of finding early stage lung
cancers.
Three independent analysis of six prospective CT screening
studies suggest a potential mortality reduction benefit of
20%. In a large collaborative study the International Early
Lung Cancer Action Program Investigators screened 31 567
asymptomatic persons at risk for lung cancer with LDCT
scanning from 1993 to 2005, suggesting that the stage I
detection rate on 484 diagnosed lung cancers and 10-year
survival rate could both exceed 80%.
At the same time, however, an analysis of three
prospective trials on 3246 persons suggested that the use of
LDCT could not reduce significantly the mortality from lung
cancer.
Major concerns still remain about the potential over-
diagnosis and follow-up of the number of detected nodules as
well as about cost and healthcare policy questions of lung
cancer screening; it is necessary to await the completion and
maturation of some prospective randomized trials such as the
one designed and conducted by the National Cancer Institute
(USA), the National Lung Screening trial comparing spiral CT
and chest X-ray screening for early lung cancer detection to
definitively evaluate the relevance of screening in early
diagnosis of NSCLC. At the moment it is clear that chest X-rays
cannot be recommended for screening of lung cancer.
recommendation IA
Low-dose CT scan cannot yet be used for screening of lung
cancer unless in a clinical trial.
recommendation IIC
Accurate staging procedures are critical to define optimal
therapeutic strategies and prognosis in early stages NSCLC.
Recently a new lung cancer staging system has been
published by the International Association for the Study of
Lung Cancer (IASLC), based upon data regarding TNM
descriptors which have been intensively validated internally and
externally. CT scan and positron emission tomography (PET)
are widely used on a systematic basis to define the mediastinum
nodal status which remains a critical discriminant in NSCLC
staging. Sensitivity and specificity of CT scanning for
identifying mediastinal lymph node metastasis are 51%
[confidence interval (CI) 47%–54%] and 85% (CI 84%–88%);
meanwhile sensitivity and specificity of PET scanning are 74%
(CI 69%–79%) and 85% (CI 82%–88%), demonstrating that
PET scanning is more accurate in mediastinum staging and has
great relevance in the search for distant metastasis. Biopsy is
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mandatory to confirm CT and PET abnormal findings. In
patients amenable for radical surgery with curative intent PET
scanning is recommended for staging.
recommendation IA
In the case of abnormal results on PET scan with mediastinal
lymph node enlargement a biopsy of mediastinal lymph node is
recommended, through different invasive techniques for
confirmation of the N2–N3 node status such as
mediastinoscopy TBNA, EBUS-NA.
recommendation IA
surgery for stage I and II
Surgery remains the cornerstone of early stage NSCLC
treatment, but only in stage pI is 5-year survival over 50%
(ranging from 73% in stage pIA to 58% in stage pIB), with
much room for improvement with systemic adjuvant or
neoadjuvant approaches in stages II and III.
Lobectomy including systematic lymph node dissection is
considered standard of care for stage I and II NSCLC resulting
in a 5-year survival for pIA ranging from 69% to 89%, for pIB
from 52% to 75%, for pIIA from 45% to 52% and 33% for
pIIB. A pneumonectomy is rarely indicated in these stages.
Operative mortality is reported to be 3.7% in average and
ranges from 1% to 7.6%. In specialized centres mortality is
expected to be clearly <2%.
Sublobar resection of small peripheral tumours includes
anatomical segmentectomy and large wedge excision. The only
randomized controlled study for stage I tumours found
significantly higher local recurrences in the segmentectomy
group with a trend, but not significant survival benefit for
lobectomies. Further studies including a meta-analysis
confirmed that 5-year survival is similar for stage I and
therefore recommendations are that patients unfit for
lobectomy should undergo a segmentectomy. Minimally
invasive video-assisted (VATS) lobectomy is continuously more
and more applied in many centres for tumours generally <5 cm.
A recent meta-analysis reported similar locoregional
recurrences for VATS compared with open lobectomy but
a reduced systemic recurrence rate (P = 0.03) and improved
5-year survival rate (P = 0.04). The latter may be partially due
to a selection bias in the VATS group. However, VATS
lobectomy is associated with lower morbidity, shorter hospital
stay and facilitates the delivery of adjuvant chemotherapy.
Radiotherapy is a reasonable opportunity for those patients
not candidates for surgery because of medical comorbidities or
refusing surgery. Local recurrence occurred at a median rate of
40% and median survival was reported as between 18 and 33
months. Results have been improved by modern techniques of
radiotherapy, administered in larger doses, fewer fractions and
smaller fields with three-dimensional conformal radiotherapy.
Local recurrent rate has been reduced around 14.5%.
recommendations
For healthy patients with stage I–II lobectomy represents the
treatment of choice [I, A]. Fractionated or conformal
stereotactic radiotherapy should be offered to medically
unoperable patients [I, B].
adjuvant chemotherapy in early stage
NSCLC
Adjuvant chemotherapy has been considered a standard
modality of cure after surgery in breast and colorectal cancer
with the highest level of evidence and recommendation, but
just in the last 10 years it has become a recommended
treatment for early stage NSCLC. In 1995 a first meta-
analysis of all randomized trials of adjuvant chemotherapy
versus best supportice car (BSC) (or observation) performed
on the basis of individual data, showed an absolute survival
benefit of 4% at 5 years, for modern cisplatin-based
chemotherapy regimens, with a non-statistically significant
trend in survival benefit. In this meta-analysis it was clear
that the survival benefit would result from the 11 trials of
cisplatin-based regimens, whilst the previous use of
alkylating agents was detrimental in comparison with
observation.
The results of a 1995 BMJ meta-analysis prompted a number
of randomized clinical trials which have been completed and
published, for an accrual of >7000 patients, with conflicting
results (Table 1). Two studies, one by ECOG with cisplatin–
etoposide plus radiotherapy and one by ALPI-EORTC using the
MIP regimen (mitomycin–ifosfamide–cisplatin), failed to show
any survival benefit in comparison with observation in stage
I–II–IIIA radically resected patients.
In the ECOG trial, the concomitant chemoradiotherapy
potentially could have harmed the treated patients reducing the
cisplatin dose intensity below an active threshold level. In the
ALPI-EORTC trial, the choice of MIP regimen—at that time
considered as a reference combination—could have negatively
influenced dose intensity and survival.
A similar trial, the Big Lung Trial (BLT), was performed in
the UK exploring the value of cisplatin-based chemotherapy
versus observation in fully resected stage I–II–III NSCLC.
This study enrolled only 381 patient without adequate
power to detect any survival difference and included
stages I–III, failing to show any benefit for the adjuvant
treatment.
In 2004 the International Adjuvant Lung Cancer Trial (IALT)
published the results of the largest adjuvant chemotherapy
study ever done, in 1867 fully resected stage I–III NSCLC,
randomized to receive three or four cycles of cisplatin
combined with vinblastine, vinorelbine or etoposide versus
observation; postoperative radiotherapy (PORT) was
performed on the basis of individual centres’ decision. This
study was the first positive adjuvant trial with a statistical
survival benefit in favour of chemotherapy in both disease-free
and overall survival. In the IALT trial 37% of the patients had
stage I, 24% stage II and 39% stage III, and stage III patients
obtained the largest benefit from chemotherapy. A higher
cumulative cisplatin dose (240 mg/m2) and the application of
PORT in stage III in the IALT trial, could explain the better
outcome in comparison with the results of the ECOG, ALPI-
EORTC and BIG trials. In a recent update, the IALT
investigators reported that the survival benefit in favour of
chemotherapy was non-significant after a median follow-up of
90 months, probably because of more non-cancer-related
deaths in the chemotherapy-treated patients.
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The IALT results have been later confirmed in two similar
trials, designed to evaluate the combination of cisplatin and
weekly vinorelbine for up to 16 weeks as adjuvant treatment.
The National Cancer Institute of Canada designed its trial in
482 fully resected NSCLC stage IB–II, with a significant survival
benefit, obtained only in stage II patients. Neutropenia grade
III–IV was present in 88% and febrile neutropenia in 7% of the
cases. In the chemotherapy arm median survival was
significantly prolonged at 94 months as compared with 73
months in the observation groups; a preplanned subgroup
analysis did not show improvement in overall survival for stage
IB patients.
The same regimen has been also evaluated in a prospective,
randomized study, carried out by the Adjuvant Navelbine
International Trialist Association (ANITA) in 840 fully resected
stage IB–III patients: in these study postoperative radiotherapy
was planned in node-positive patients and 232 patients received
postoperative radiotherapy (33.% in the observation and 22%
in the chemotherapy arm). A retrospective analysis showed that
median survival was longer in patients with stage III–N2 disease
both in the chemotherapy and the observation arm suggesting
a positive role for adjuvant radiotherapy in stage III patients.
The ANITA trial confirmed the poor compliance of the
vinorelbine–cisplatin schedule with 86% of grade III–IV
neutropenia and 9% of febrile neutropenia. After 76 months of
median follow-up, the median overall survival was significantly
longer in the chemotherapy arm but, at subgroup analysis the
benefit was limited to stage II–III patients.
In 2005, the CALGB presented the preliminary results of
a prospective randomized trial of adjuvant carboplatin–
paclitaxel administered to fully resected patients with stage IB
disease, showing a significant reduction at 4 years.
Unfortunately, these results were not confirmed at 6-year
follow-up, except in an unplanned subset analysis of patients
with tumour size >4 cm. This finding opened a still unsolved
controversy of whether patients with stage IB tumours should
be treated with systemic adjuvant chemotherapy. In the new
UICC 7 classification, T2 N0 tumours >5 cm in diameter will be
reclassified as stage IIA instead of IB, which could solve this
controversy.
The Spanish NATCH trial, designed to detect differences in
outcome between preoperative chemotherapy, postoperative
chemotherapy and surgery alone was recently reported. A total
of 624 patients were randomized between surgery with or
without adjuvant or neoadjuvant three cycles of carboplatin
and paclitaxel. No difference in outcome was observed between
the two arms, possibly due to the predominance of stage I
patients.
meta-analyses (Table 2)
These last five large randomized trials have been pooled in an
individual patient database LACE (Lung Adjuvant Cisplatin
Evaluation) meta-analysis of 4584 patients, showing that
adjuvant chemotherapy increases survival from 64% to 67% for
stage IB, from 39% up to 49% for stage II and from 26% up to
39% for stage III NSCLC at a median follow-up of 5.1 years.
The meta-analysis confirmed a potential detrimental effect of
chemotherapy in stage IA.T
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In 2007, the update of the 1995 NSCLC collaborative group’s
individual patient data meta-analysis, reviewing data of 8147
patients of 30 randomized trials, demonstrated a significant
survival benefit for adjuvant cisplatin-based chemotherapy,
with an absolute benefit of 4% (from 60% to 64%) at 5 years.
On the basis of this level 1 evidence, there is a widespread
consensus that cisplatin-based doublet adjuvant chemotherapy
improves disease-free survival and 5-years overall survival in
completely resected patients with stage II–IIIA NSCLC.
However, not all the NSCLC early stage patients are potential
candidates to receive adjuvant chemotherapy: a significant
proportion of NSCLC cases is diagnosed among patients >70
years and because of prolonged smoking exposure most of
them present with relevant cardiovascular, pulmonary and
metabolic comorbidities which can significantly reduce
chemotherapy compliance and increase the side-effects of
cisplatin-based treatment.
In current clinical practice, the best candidate for adjuvant
chemotherapy is a relatively young patient, in good condition
and without significant comorbidities, who undergoes
a complete resection by lobectomy for an early stage NSCLC
and recovers quickly from surgery. In the adjuvant setting an
absolute benefit of 4%–5% in 5-year survival is considered
worthwhile to recommend chemotherapy in current clinical
practice after surgery in breast, colorectal and today also
NSCLC. However, also in carefully selected patients compliance
with chemotherapy in recent randomized trials seems to be
moderate and a significant number of patients experience dose
reduction, or delays or interruption of treatment. These data
reopen the strategic question of whether the more appropriate
systemic treatment of early stage NSCLC should consist of
neoadjuvant or adjuvant chemotherapy.
recommendations
Three large randomized trials very similar in design and
chemotherapy regimens showed a significant survival benefit
for the treatment arm in stage II and III radically resected
patients with HR ranging from 0.70 to 0.80 and 0.86. In all
studies cisplatin-based doublets were used, mainly cisplatin–
vinorelbine, with a cisplatin dose >80 mg/m2 and the survival
benefit was consistent across the trials for stage II–IIIA. Besides
these studies a number of smaller trials addressing the same
questions have been completed and published in these years
showing similar results.
Subsequentially a meta-analysis based on individual patient
data on 4584 patients has been published 13 years later than the
first meta-analysis of the BMJ. It confirmed that adjuvant
cisplatinum-based chemotherapy increases survival from 64%
to 67% for stage IB NSCLC, from 39% to 49% for stage II
NSCLC and from 26% to 39% for stage III NSCLC. These data
have been substantially confirmed by three different literature-
based meta-analyses recently published, exploring the
magnitude of benefit of cisplatin-based adjuvant
chemotherapy. On the basis of the LACE meta-analysis, of the
update of the 1995 BMJ meta-analysis and of the single
randomized published studies, the evidence in favour of
adjuvant cisplatin-based chemotherapy has been confirmed and
strengthened and constitute a rational basis for the ESMO
Table 2. systematic reviews and meta-analyses addressing adjuvant chemotherapy
Reference Intervention/control Number of
participants/
(number of
studies)
Difference in 5
year survival
(%)/(95% CI)
HR/95% CI P-value Remark
NSCLC-CG, 1995 [10] Resectiion 6 cisplatin–POCT 1394 (8) +5 (–1; +10) 0.87 (0.74–1.02) 0.08 IPD
NSCLC-CG, 1995 [10] Resection + PORT 6
cisplatin–POCT
807 (7) +2 0.98 (–14 to +17) 0.76 IPG
Sedrakyan, 2004 [32] Resectie 6 POCT 7200 (19) NS 0.87 (0.81–0.93) <0.0001
Resection 6 cisplatin
–POCT
4912 (12) NS 0.89 (0.82–0.96) 0.004 NNT: 25
Hotta, 2004 [31] Resection 6 POCT 5360 (13) NS 0.87 (0.80–0.94) 0.001
Resection 6 cisplatin
–POCT
3786 (8) NS 0.89 (0.81–0.98) 0.012
Berghmans, 2005 [51] Resection 6 POCT 7644 (17) NS 0.84 0.78–0.89 NV Systematic review
Resection 6 cisplatin
–POCT
NV (16) NS 0.86 (0.80–0.92) NV
Bria, 2005 [33] Resection 6 platinum
–POCT
4612 (10) 3.9 0.92 (0.87–0.97) NV NNT: 21; pooled
analysis
LACE, 2006 [29] Resection 6 cisplatin
–POCT
4584 (5) 4.2 0,89 (0,82–0,96) <0.005 IPD
NSCLC-CG, 2007 [30] Resection 6 cisplatin
–POCT, no PORT
8147 (30) 4 0.86 (0.81–0.93) <0.001 IPD
NSCLC-CG, 2007 [30] Resection + PORT 6
cisplatin–POCT
2763 (12) 4.43 0.90 (0.82–0.98) 0.02 IPG
NNT, number needed to treat; NS, not stated; POCT, postoperative chemotherapy; PORT, postoperative radiotherapy; IPD, individual patient data.
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Clinical Practice Guidelines in favour of adjuvant
chemotherapy in the stage II–III radically resected NSCLC
patient with Recommendation IA.
neoadjuvant chemotherapy in stage
I–IIA NSCLC
Neoadjuvant or preoperative chemotherapy is still considered
an experimental modality of treatment mainly because it has
been evaluated in only a small number of randomized trials and
in a series of small phase II studies, exploring the safety and
activity of different platinum regimens. Theoretically the
neoadjuvant approach has a number of advantages: it can
reduce the tumour volume and facilitate the control of
micrometastatic diffusion or prevent it; the neoadjuvant
treatment allows a careful evaluation of chemotherapy response
giving critical information on tumour biology in adequate
tumour samples: the compliance of chemotherapy in untreated
patients is certainly better than after surgery and its dose
intensity higher. On the other hand, its toxicities and a delay to
surgery could be disadvantages, although up to now these issues
seem to be scarcely relevant.
Two small randomized trials comparing neoadjuvant
chemotherapy and surgery versus surgery alone in stage IIIA
have raised considerable interest and had a profound impact in
the scientific community and in clinical practice. These trials
were designed to compare induction platinum-based
chemotherapy (with different regimens) followed by surgery
versus surgery alone. Roth et al. compared three cycles of
cisplatin–etoposide and cyclophosphamide and surgery with
surgery alone in stage IIIA in 60 patients, resulting in
a 64-month median survival for the combined arm versus 11
months for the control arm with an impressive statistical
benefit, which, however, vanished after 82 months of follow-up
to 21 and 14 months of median survival, respectively, with
borderline statistical significance. Similar results were obtained
by Rosell et al. in which the poor outcome of the surgery arm
could be attributed to a negative imbalance of biological
prognostic factors. The study was prematurely interrupted on
the basis of an interim analysis and showed a median survival of
22 months versus 10 months in favour of the (combined)
experimental arm, but was also not confirmed in a subsequent
identical larger trial from the same Spanish investigators. Pass
et al. randomized 27 patients between surgical resection either
preceded by cisplatin–etoposide chemotherapy or followed by
radiotherapy and observed median survival times of 29 versus
16 months. The results of this trial are, however, difficult to
interpret due to the asymmetry in randomization. Other small
randomized series did not observe a difference in outcome
between approaches with or without preoperative
chemotherapy.
These earlier trials have a number of weaknesses in their
design: a variable use of adjuvant chemo- and radiotherapy; the
use of first- and second-generation drugs, some of which have
been associated with a detrimental effect on survival and the
use of the 1986 staging classification, in which stage III is even
more heterogeneous than in the present one and inappropriate
staging resulting in an imbalanced distribution of various stages
in the two arms.
In 2001, the results of a French phase III randomized trial of
induction mitomycin, ifosfamide, cisplatin chemotherapy in
resectable stage IB, II and IIIA were reported. Three hundred
and fifty-five eligible patients were randomized to surgery alone
or combined modality therapy consisting of two cycles of
chemotherapy followed by surgery. Responding patients
received two additional cycles of adjuvant chemotherapy. The
arms were well balanced for patient characteristics with the
exception that fewer clinically N2 patients were assigned to the
surgery-only arm (28% versus 40%). A non-significant excess
of postoperative morbidity in the chemotherapy arm was seen
(24/167 versus 22/171). Postoperative mortality was 7% in the
chemotherapy arm and 5% in the surgery arm (P = 0.38).
Median survival was improved by 11 months (37 versus 26
months) and at 4 years, there was a 9% increase in survival in
the chemotherapy arm, but this did not achieve statistical
significance. No difference was seen in local recurrence rates. A
significant decrease in distant metastases was observed
favouring the chemotherapy arm. Follow-up data on this trial,
when minimal follow-up exceeded 60 months, showed that the
3- to 5-year survival differences were stable at 10%.
Statistically significant benefits in the N0–1 subgroup were
confirmed with 5-year survival rates of 49% compared with
34% in the N2 subgroup.
At least five randomized trials have further explored the issue
of neoadjuvant chemotherapy. A common feature of these trials
is that they have all been confronted with accrual problems,
leading in some studies to their early closure, when the results
of randomized trials showing a benefit of adjuvant
chemotherapy were published.
The Southwest Oncology Group trial S9900, was a phase III
randomized study comparing induction paclitaxel/carboplatin
chemotherapy for three cycles followed by surgery with surgery
alone in clinical stage IB, II and IIIA NSCLC (excluding
superior sulcus and N2 disease) (Table 3). Mediastinoscopy was
performed whenever the mediastinal lymph node size exceeded
1 cm. PET imaging was not required. The study called for 600
patients to detect a 33% increase in median survival or 10%
increase in 5-year survival but the accrual was prematurely
suspended at a total of 354 patients. Of the patients randomized
to chemotherapy, 79% completed three cycles of
chemotherapy, 41% had radiographic response and 94% had
complete resection. Eighty-nine per cent of patients on the
control arm had complete resection. With a median follow-up
of 53 months, median and 5-year survival rates were 75 versus
46 months, and 50% versus 43% for the chemotherapy–surgery
and surgery-alone arms, respectively. Although the use of
chemotherapy was associated with a 19% reduction in the risk
of death, this difference did not achieve statistical significance.
Progression-free survival trended in favour of neoadjuvant
chemotherapy, with a median of 33 months versus a median of
21 months for immediate surgery.
In the European Intergroup trial MRC-LU 22 EORTC-08012
NVALT-2, 519 patients with resectable early stage NSCLC
were randomized to either surgery alone or three cycles of
platinum-based chemotherapy followed by surgery. Choice of
chemotherapy regimen was at investigator’s choice, as was the
intensity of preoperative staging, resulting in only a quarter of
the patients being staged with mediastinoscopy and/or PET
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Table 3. Summary of four randomized trials comparing neoadjuvant chemotherapy with immediate surgery
Study/reference SWOG 9900 [46] European Intergroup Trial [47] Ch.E.S.T. [49] NATCH [28]
Immediate
surgery
Neoadjuvant
chemotherapy
Immediate
surgery
Neoadjuvant
chemotherapy
Immediate
surgery
Neoadjuvant
chemotherapy
Immediate
surgery
Neoadjuvant
chemotherapy
No. patients 167 169 261 258 141 129 210 199
Accrual interval 1997–2005 1999–2004 2000–2004 2000–2007
Chemotherapy
Regimen(s) 100% Cisplatin–vinorelbin (45%) 100 100
Carboplatin
AUC 6
Cisplatin–gemcitabine (25%) Cisplatin 75
mg/m2 day 1
Carboplatin
AUC 6 d1
Paclitaxel 225
mg/m2
Carboplatin–docetaxel (12%) Gemcitabine 1250
mg/m2 days 1,8
Paclitaxel 200
mg/m2 d1
Mitomycin–vindesin–
cisplatin (12%)
Mitomycin–ifosfamide–
cisplatin (7%)
Frequency q 3 w · 3 q 3–4 w · 3 q 3 w · 3 q 3 w · 3
Compliance (%) 79 75 1 85
Patient and tumour
characteristics
Age (median) 64 65 63 62 63 61 64 65
Female gender (%) 32 36 28 28 11 22 12 24
c stage I (%)a 67 68 59 64 54 43 73 74
c stage II (%)b 32 33 35 28 43 52 25 23
c stage IIIA (%) NA NA 6 8 2 5 2 2
Squamous cell (%) 42 34 48 51 45 37 50 54
Response on chemotherapy
Clinical objective response
(%)
41 (CR: 3) 49 (CR: 4) 35 53
PD during chemo (%) 7a 6 6 5
Pathological CR (%) <10 4 NA 10
Safety of chemotherapy
Neutropenia (grade
3–4) (%)
48 NA 26 12.4
Myalgia/arthralgia (grade
3–4) (%)
6/7 NA 2.6
Mortality: number (%) 3 1 1 (0.5)
Surgical results
Operated on (%) 96 97 93 91 96 85 95 91
Downstaging NA NA 18 31 NA NA
Complete resection (%) 89 94 79 81 NA NA NA NA
Pneumonectomy rate (%) 25 24 33 28 24 10 26 23
p stage I (%) NA NA 47 59 NA NA 48 49
c
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scan. This trial was also prematurely closed for slowing accrual
and its results reported. Of the patients randomized to
chemotherapy, 75% completed three cycles of chemotherapy,
49% had radiographic response and 81% had complete
resection. Seventy-nine per cent of patients on the control arm
had a complete resection. With a median follow-up of 41
months, median and 5-year survival rates were 54 versus 55
months, and 44% versus 45% for the chemotherapy–surgery
and surgery-alone arms, respectively. A peculiar finding is the
inaccuracy of clinical staging: whereas 18% of the patients who
were resected without neoadjuvant chemotherapy actually had
a lower pathological than clinical stage, and 41% were
likewisely ‘upstaged’. Patient quality of life seemed not to suffer
from the use of chemotherapy and the delayed resection.
A Scandinavian randomized phase II trial reported in
abstract a HR of 0.89 in favour of neoadjuvant chemotherapy.
In the Ch.E.S.Trial, prematurely closed in August 2004, 236
patients with early stage NSCLC were randomized to either
surgery alone or three cycles of cisplatin and gemcitabine
followed by surgery. Preliminary 3-year survival data favour
neoadjuvant chemotherapy, but should be confirmed at 5 years.
In the Spanish NATCH trial, 624 patients were randomly
allocated to immediate surgery or to three cycles of
neoadjuvant carboplatin and paclitaxel followed by surgery. No
difference in outcome was observed between the two arms, with
the exception of a non-significant trend towards improved
disease-free survival with neoadjuvant chemotherapy which
became significant in stage II T3 N1 at subgroup analysis. This
trial confirmed the better compliance with preoperative
chemotherapy (97%) as compared with adjuvant (61%) and
showed similar resectability rates, surgical procedures and
postoperative mortality across arms.
Besides their low power and accrual, these trials have two
further weaknesses in common: the survival in their control
arms treated with immediate surgery is better than initially
estimated, confounding the underpowering caused by the early
closure of these trials; stage I (clinical or pathological)
accounted for >50% of the enrolment and hence of the better
than expected survival. As the accumulated evidence in the
adjuvant setting has not found a statistically significant survival
benefit for adjuvant chemotherapy in stage I disease, the
implication of this finding in the neoadjuvant setting might
imply that a possible benefit for higher stages has been diluted
by the majority of stage I cases.
meta-analyses (Table 4)
Two systematic reviews from published summary data of
randomized chemotherapy trials in early stage NSCLC have
been published. The meta-analysis by Berghmans et al. reported
six randomized trials, including 590 patients, published
between 1990 and 2003. The overall fixed-effect HR on survival
was 0.69 (95% CI 0.57–0.84) in favour of the addition of
neoadjuvant chemotherapy to surgery. A less extreme result was
seen in the publication by Burdett et al. Data from seven
randomized trials (published between 1990 and 2005),
including 988 patients, were combined in a systematic review
and meta-analysis. Preoperative chemotherapy improved
survival with a HR of 0.82 (95% CI 0.69–0.97), equivalent to anT
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absolute benefit of 6% at 5 years. They furthermore found an
incremental benefit by stage: stage IA: + 4%, stage IB: 6%; stage
II–III: + 7%, but did not observe any interaction between the
kind of platinum-containing regimen or the kind of adjuvant
treatment (chemo- or radiotherapy). The exploratory nature of
these subgroup analyses warrants an IPD approach, which is
ongoing. Gilligan et al. added the mature results of the
European Intergroup trial to the previous meta-analysis and
observed a shift of the hazard ratio to 0.87, with loss of the
significance of the improvement in outcome (Figure 1).
recommendations
The available outcome data trend in favour of neoadjuvant
therapy, but the majority of individual trials did not find
a statistically significant benefit. This could be due to the
underpowering of the individual studies or contamination of
the outcome by the use of adjuvant therapy in some of them.
The data of both systematic reviews on the other hand show an
overall effect which is significantly in favour of neoadjuvant
treatment. The size of the observed effect is comparable to the
one described in a similar meta-analysis of adjuvant
chemotherapy. One must keep in mind that both patient
populations are different, as only selected patients are offered
adjuvant chemotherapy, after pathological staging. The lack of
clinicopathological correlation observed in the European
Intergroup trial illustrates the heterogeneity of patients enrolled
on neoadjuvant trials.
Neoadjuvant chemotherapy results in a clinical downstaging
in 40%–60% of the patients and a pathological complete
response rate in 5%–10%. As expected, compliance is better
with neoadjuvant chemotherapy compared with adjuvant
treatment: >90% of the patients are able to complete all three
cycles of neoadjuvant chemotherapy, whereas the full planned
adjuvant chemotherapy could only be administrated in
45%–60% of patients.
With the present status of knowledge, neoadjuvant regimens
should be platinum based and at least three cycles of
chemotherapy should be administered. As in advanced NSCLC,
a two-drug combination of platinum and a third-generation
drug seems preferable: preoperative cisplatin-based
combination chemotherapy can be considered in patients with
stage IIIA–N2 disease.
recommendation IIB
locally advanced NSCLC (stage III)
Locally advanced or stage III disease accounts for 30% of
patients with NSCLC. Treatment of stage III NSCLC remains
a very difficult and controversial area mainly because of the
large heterogeneity of different pathological conditions that are
still included in stage III in the last update of the TNM
classification of lung cancer. Locally advanced NSCLC has been
for many years divided into stage IIIA with a 24% 5-year
survival and stage IIIB with a worse prognosis and 5-year
survival of 9%. Stage IIIA NSCLC represents a heterogeneous
group of patients whose tumour extension is restricted to the
affected lung (T3 N1), but also includes patients with
metastatic disease to the ipsilateral mediastinal lymph nodes
(T1–3 N2). Approximately 10%–15% of newly diagnosed cases
with NSCLC will be classified as stage IIIA–N2. Their
presentation ranges from apparently resectable tumours with
occult nodal microscopic metastasis to unresectable, bulky
multistation nodal disease. Taken into account this substantial
heterogeneity, stage III NSCLC has been classified into six
subsets (Table 5).
The poor survival with surgery alone has led to efforts to add
chemo- and/or radiotherapy to the locoregional treatment. As
mentioned in an above-mentioned meta-analysis, the subgroup
of pIIIA patients (subsets 0–2) has a 17%–20% reduction in the
risk of death with adjuvant chemotherapy, improving their 5-
Table 4. Meta-analysis of outcome of peri-operative platinum-based
chemotherapy in NSCLC
HR (95% CI) Adjuvant
chemotherapy
Neoadjuvant
chemotherapy
Early evidence 0.86 (0.80–0.92) 0.66 (0.48–0.93) [50]
Recent evidence 0.89 (0.82–0.96) 0.88 (0.76–1.01) [51]
Figure 1. Twelve per cent relative survival benefit with the addition of neoadjuvant chemotherapy (1507 patients; HR = 0.88; P = 0.07), equivalent to an
absolute improvement in survival of 5% at 5 years.
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year survival rate by 13%–15%. This benefit on overall survival
was, however, smaller in an individual patient data meta-
analysis of randomized trials addressing the benefit of adjuvant
chemotherapy on surgery, but included an improved local
recurrence-free interval and persisted when PORT was added to
surgery. There is hence little controversy that adjuvant
chemotherapy should be given to those resected patients
presenting with pIIIA subsets 0–2.
PORT in pN2 patients has been shown to result in no clear
difference in overall survival but a small reduction in local
recurrence. Results from a subgroup analysis of a randomized
trial addressing adjuvant chemotherapy and from
a retrospective epidemiological study, however, indicates
a benefit of PORT on overall outcome in stage IIIA. This issue
is currently being prospectively studied in the LUNG-ART trial.
Twelve randomized trials have compared neoadjuvant
chemotherapy followed by surgery versus surgery alone in
patients with stage IIIA NSCLC with variable numbers of N2
involvement. A number of these trials have not yet been
published as full papers. Table 6 summarizes the available
evidence as pooled analyses of survival data of these trials. It
can be concluded that a significant benefit in favour of
neoadjuvant chemotherapy is present ranging at 5 years from
6% to 14% albeit weakened by confounding factors as the non-
homogeneity of the patients included, the inadequate sample
size and the variable addition of postoperative treatments. In
the above-mentioned meta-analysis of neoadjuvant
chemotherapy in patients with resectable NSCLC, the analysis
by stage shows a 6%–7% absolute benefit in 5-year survival in
cIIIA patients, improving their outcome from 15%–35% to
21%–42%. Specific data regarding the subset IIIA–N2 are,
however, lacking.
Two randomized clinical trials have been completed in
Europe and North America aimed at evaluating the role of the
addition of surgical resection to an induction regimen in
patients with clinically proven stage IIIA–N2 NCLC, considered
functionally operable (Table 7). In the EORTC trial, patients
with documented IIIA due to unresectable N2 (disease) NSCLC
received as induction chemotherapy three cycles of platinum-
based chemotherapy: 332 responding patients were then
randomly allocated to receive surgery or radiotherapy, the latter
consisting of at least 60 Gy to the primary tumour and 40–46
Gy to mediastinum; PORT was later given to 62 (40%) patients
in the surgical arm. Median survival time and 5-year overall
Table 5. subclassification of stage III
Subset Definition
IIIA–0 T3 N1 or T4 N0–1 without N2 involvement
IIIA–1 Incidental nodal metastases found on final pathology
examination of the resection specimen
IIIA–2 Nodal (single station) metastases recognized
intraoperatively
IIIA–3 Nodal metastases (single or multiple station) recognized
by prethoracotomy staging (mediastinoscopy, other
nodal biopsy, or PET scan)
IIIA–4 Bulky or fixed multistation N2 disease
IIIB Nodal metastasis in N3 lymph nodes
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survival rates were 16.4 months and 16% in the surgical arm,
and 17.5 months and 14% in the radiotherapy arm. In the
surgery arm only 50% resulted in complete resection due to the
study design. The conclusions were that surgery did not
improve overall or progression-free survival compared with
radiotherapy in stage III A unresectable N2 patients responding
to induction chemotherapy.
In the phase III randomized North American Intergroup
Trial, 492 patients with pathologically documented stage IIIA–
N2 NSCLC were randomly assigned to either concurrent
chemoradiotherapy therapy (two cycles of cisplatin and
etoposide plus radiotherapy interrupted at 45 Gy) followed
by surgery (trimodality treatment), or the same
chemoradiotherapy with uninterrupted definitive radiotherapy
up to 61 Gy. Two additional consolidation cycles of cisplatin
and etoposide were given in both groups. Overall survival was
not significantly improved with the addition of surgery, even
though progression-free survival was significantly better and
local-only relapse rates were lower in patients who underwent
trimodality treatment. The most probable reason for the
observed lack of improved outcome with surgery relates to the
exceedingly high mortality rate after pneumonectomy, mainly
attributable to acute respiratory distress syndrome and other
respiratory causes, and not observed in other centres or single
institutional series. Other reasons might include an inadequate
study power and the reduced delivery of the adjuvant
chemotherapy in the surgical group. However, whether the
consolidation chemotherapy had any effect in the non-surgical
setting is unknown. The authors did an exploratory matching
analysis between resected and not resected patients that led to
the hypothesis that trimodality treatment could be beneficial if
a complete resection with lobectomy is done after induction
chemoradiotherapy, and if the increased surgical mortality
associated with pneumonectomy is avoided. This type of
analysis is, however, prone to bias because of the absence of
matching for other possible prognostic factors such as gender,
age and different biomarkers.
Although it is hazardous to make intertrial comparisons
between the results of EORTC 08941 and InterGroup 0139, the
following conclusions can be drawn.
 Both trials show equivalence in overall survival between surgery
and thoracic radiotherapy. The operative morbidity and
mortality is also higher than with radiotherapy in both trials,
suggesting that for a similar outcome, a preference is to be given
to the safest approach, regardless of the IIIA subgroup studied.
Although this does not mean that surgery is not feasible or is
inferior to radiotherapy, the results neither justify a presumption
of superior efficacy of thoracic surgery in subgroups, nor
a defeatism against radiotherapy. In the absence of high-quality
comparative outcome studies, the available institutional
expertise with both approaches and observed clinical outcomes
should determine the local approach.
 The rate of pathological nodal downstaging is low,
confirming the low accuracy of radiological response
assessment (see further) and a low activity of the induction
regimens used. The rate of complete pathological remission
with neoadjuvant chemotherapy is lower than with
chemoradiotherapy, confirming the results of other series.
Interestingly, although mediastinal downstaging occurred in
48% of patients allocated to the trimodality treatment in the
Intergroup trial, only 15% of them had a pathological
Table 7. Randomized trials in stage IIIA–N2 NSCLC comparing surgery and radiotherapy as locoregional modalities after induction chemo(radio)therapy
Study (reference) EORTC 08941 [55] Intergroup 0139 [56]
Treatment arm Induction chemotherapy +
surgery
Induction chemotherapy +
radiotherapy
Induction
chemoradiotherapy + surgery
Chemoradiotherapy
Number of patients with
IIIA–N2
167 166 202 194
Chemotherapy regimen Platinum based – Cisplatin–etoposide –
Radiotherapy total dose
(Gray)
– 60 45 61
Rate of pneumonectomy/
(bi-)lobectomy/exploratory
thoracotomy (%)
47/38/14 – 27/49/4 –
R0 resection rate(%) 50 – 71 –
Treatment related mortality
rate (%)
4 <1 8 2
Pathological nodal
downstaging rate (%)
41 (pN0–1) – 38 (pN0) –
Pathological complete
response rate (%)
5 – 15 –
Median PFS (months) 9.0 11.3 12.8 10.5
Locoregional failure rate (%) 32 55 10 22
Median OS (months) with
95% CI
16.4 (13.3–19.0) 17.5 (15.8–23.2) 23 22.2
5 year SR (%) with 95% CI 15.7 (10–22) 14 (9–20) 27.2 20.3
PFS, progression-free survival; OS, overall survival; R0, microscopically radical resection; SR, survival.
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complete response after 45 Gy of radiotherapy, suggesting an
inappropriate dose of the latter to sterilize the primary
tumour.
 In both trials local control with surgery is better than with
radiotherapy, as the locoregional relapse rate in the EORTC
study was higher with radiotherapy and progression-free
survival was better in the Intergroup trial. Although this
observation can be credited to the surgical resection only, it
cannot be excluded that the administration of PORT in the
EORTC trial and an imbalance in the consolidation
chemotherapy in the Intergroup trial are responsible for this
finding, as both modalities have been shown to reduce local
control. This finding suggests a role for resection as
consolidation after definitive chemoradiotherapy.
 Exploratory subgroup analyses of both trials show an
improved outcome in patients who are downstaged, and/or
in whom a complete resection can be obtained with
a lobectomy, as compared with either operated patients
without these features, or matched irradiated patients. This
finding requires further validation in an adequately designed
trial in which patients downstaged after definitive
chemoradiotherapy are randomly allocated to either
consolidation resection or not.
unresectable locally advanced stage III
NSCLC
recommendations
In patients with stage IIIB or stage IIIA–N2 subset 4, several
meta-analyses allow the following conclusions (Table 8).
1. Adding platinum-containing chemotherapy either at
systemic doses preceding or at low radiosensitizing dose
concomitant with chest radiotherapy in good
performance patients significantly improves the outcome
as compared with single modality chest radiotherapy with
traditional dose and fractionation schedules (1.8–2.0
Gy per fraction per day to 60–70 Gy in 6–7 weeks),
which yields poor survival rates and patterns of failure
that are both locoregional and distant. Although the
evidence was already observed in a previous meta-
analysis, the latter did not specifically analyse for stage
IIIA and for the sequence in which both modalities were
administered.
recommendation IA
2. Concomitant chemoradiotherapy at systemic doses results
in superior outcome to sequential chemoradiotherapy, at
the cost of a moderately increased toxic
morbidity—consisting mostly of grade 3–4
esophagitis—and is considered the present standard of
care in selected patients. Hence 5-year survival rates of
15% in a mixed population of selected stage III patients
seem achievable and are comparable to unmatched series
using a surgical approach. Cisplatin–etoposide (or
vinblastine or vinorelbine) and carboplatin–paclitaxel
both at systemic doses should be considered as the
reference regimens.
3. In all meta-analyses, the effect was observed to be
independent of patient and tumour characteristics,
substage (IIIA versus IIIB) and time period in which the
trials were conducted.
4. Definitive-dose thoracic radiotherapy should be no less
than the biological equivalent of 60 Gy, in 1.8- to 2.0-Gy
fractions to the planning target volume (PTV). Ideally,
this requires 3-dimensional (3D) conformal radiotherapy,
a technique characterized by beam outlines that match
the shape of the PTV.
recommendation IA
follow-up and surveillance of early
stage NSCLC after curative intent
treatment
Considerable controversy exists about the post-treatment
management of patients with early stages NSCLC: how often
Table 8. Individual patient meta-analyses of outcome of stage IIIA patients treated with chemoradiotherapy
Comparison Reference Arms No. patients with IIIA HR (95% CI)
Radiotherapy versus
radiotherapy combined
with platinum-based
chemotherapy
Rolland et al. [55] Radiotherapy 449 0.91 (0.79–1.05)
Platinum-based concomitant
chemoradiotherapy
548
Radiotherapy versus
sequential
chemoradiotherapy
Rolland et al. [55] Radiotherapy 723 0.87 (0.78–0.97)
Sequential
chemoradiotherapy
741
Radiotherapy versus
combined
chemoradiotherapy at
sensitizing dose
Aupe´rin et al. [58] Radiotherapy 490 0.81 (0.71–0.92)
Concomitant
chemoradiotherapy
592
Sequential versus
concomitant approach at
systemic doses of
chemotherapy
Aupe´rin et al. [59] Sequential
chemoradiotherapy
190 0.72 (0.58–0.90)
Concomitant
chemoradiotherapy
188
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and by which tests surveillance should be performed is still
debatable mainly because of the lack of evidence that earlier
treatment of recurrence leads to a better outcome. Guidelines
from different scientific societies suggest only physical
examination every 3 months (ASCO) or annual CT scan as
stated from the American College of Radiology, NCCN and
ACCP. However, a number of issues in the post-treatment time
of early stage NSCLC need to be addressed, particularly
treatment complications, recurrence of disease and
metachronous, new primary tumours.
Treatment complications related to surgery, adjuvant
chemotherapy or radiotherapy should be carefully evaluated for
a frame time of 3–6 months.
recommendation IIC
According to the published literature, in lung cancer patients
treated with curative intent in good performance status
surveillance with physical examination and CT scan is
recommended every 6 months for 2 years and then annually,
coordinated by a multidisciplinary team.
recommendation IC
Despite some reports of better sensitivity, specificity and
accuracy of PET/CT for earlier diagnosis of recurrence, this
methodology is not yet recommended, mainly because there is
no correlation between earlier detection of recurrence and
survival benefit and an intensive surveillance programme is
certainly more expensive.
recommendation IIC
Patients treated with curative intent should be encouraged
and sustained in programmes to quit smoking.
recommendation IA
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